<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<!-- saved from url=(0116)http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i1?fn=document-frame.htm&f=templates -->
<HTML><HEAD><TITLE>Clinical Evidence</TITLE>
<META http-equiv=Content-Type content="text/html; charset=windows-1252"><LINK 
href="0205_i1_files/bmj.css" type=text/css rel=stylesheet>
<META content="MSHTML 5.50.4807.2300" name=GENERATOR></HEAD>
<BODY topMargin=0>
<TABLE cellSpacing=0 borderColorDark=#ffffff cellPadding=0 width="100%" 
borderColorLight=#c2c2c2 border=1>
  <TBODY>
  <TR>
    <TD class=heading id=heading>
      <SCRIPT src="0205_i1_files/0205_i1.0"></SCRIPT>

      <SCRIPT language=JavaScript> function showWindow(targeturl) { window.open(targeturl, ""); } </SCRIPT>

      <TABLE width="100%" border=0>
        <TBODY>
        <TR>
          <TD align=right><SPAN class=localheadtopic 
            id=localheadtopic><SECTION>Cardiovascular 
            disorders</SECTION></SPAN><IMG height=10 
            src="0205_i1_files/spacer.gif" width=10 align=absMiddle 
            border=0><BR><SPAN class=localhead id=localhead><TOPIC>Primary 
            prevention</TOPIC><IMG height=10 src="0205_i1_files/spacer.gif" 
            width=10 align=absMiddle border=0></SPAN></TD></TR>
        <TR>
          <TD class=title-author id=title-author vAlign=top noWrap align=right 
          bgColor=#ffffff height=30><A 
            href="http://www.evidence.org/lpBinCE/lpext.dll?f=id&amp;id=0205_CONTRIB&amp;t=document-frame.htm&amp;2.0&amp;p="><EM>Clinical 
            Evidence</EM> writers on primary prevention</A><IMG height=10 
            src="0205_i1_files/spacer.gif" width=10 align=absMiddle 
        border=0></TD></TR></TBODY></TABLE><BR>
      <H1 
      style="DISPLAY: none; FONT-SIZE: 0pt; VISIBILITY: hidden">Antihypertensive 
      drugs</H1>
      <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
        <TBODY>
        <TR>
          <TD class=question id=question vAlign=top width="10%"><B><SPAN 
            class=question-title id=question-title>QUESTION</SPAN></B></TD>
          <TD class=question id=question>&nbsp;<B>What are the effects of drug 
            treatment in primary hypertension?</B></TD></TR></TBODY></TABLE><BR><A 
      name=I1>
      <H2 style="DISPLAY: none; FONT-SIZE: 0pt; VISIBILITY: hidden">Versus 
      placebo</H2>
      <TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
        <TBODY>
        <TR class=option id=option>
          <TD class=option id=option style="PADDING-LEFT: 2px" vAlign=top 
          width="10%"><SPAN class=option-title 
            id=option-title>OPTION&nbsp;&nbsp;&nbsp;</SPAN></TD>
          <TD class=option id=option style="PADDING-LEFT: 2px" 
            width="100%"><B>Antihypertensive drugs versus 
        placebo</B></TD></TR></TBODY></TABLE></A>
      <TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
        <TBODY>
        <TR>
          <TD><A name=I1-SUMSTATEMENT><B>
            <P style="MARGIN-LEFT: 3px" align=justify>Many systematic reviews of 
            RCTs have found that drug treatment decreases the risk of fatal and 
            non-fatal stroke, cardiac events, and total mortality in specific 
            populations of people. The biggest benefit is seen in people with 
            highest baseline risk of cardiovascular 
        disease.</P></B></A></TD></TR></TBODY></TABLE><BR>
      <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
        <TBODY>
        <TR>
          <TD>
            <P align=justify><FONT color=#0033cc><A 
            name=I1-BENEFITS><B>Benefits: </B></A></FONT>We found many systematic 
              reviews. One review (search date 1997, 17 RCTs with morbidity and 
              mortality outcomes, duration &gt;&nbsp;1 year, 37&nbsp;000 people) 
              found that antihypertensive drugs versus placebo produced variable 
              reductions of systolic/diastolic blood pressure that averaged around 
              12–16/5–10&nbsp;mm&nbsp;Hg. <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i1?fn=document-frame.htm&amp;f=templates#REF122">[122]</A> 
              It found evidence of benefit in total death rate, cardiovascular 
              death rate, stroke, major coronary events, and congestive cardiac 
              failure, but the absolute results depended on age and the severity 
              of the hypertension (see below). The biggest benefit was seen in 
              those with the highest baseline risk. The trials mainly compared 
              placebo versus diuretics (usually thiazides with the addition of 
              amiloride or triamterene) and versus ß blockers (usually atenolol 
              or metoprolol) in a stepped care approach. <font color="#FF0000">One 
              systematic review (search date 1999, 8 RCTs, 15&nbsp;693 people) 
              found that, in people over 60 years old with systolic hypertension, 
              treatment of systolic pressures greater than 160&nbsp;mm&nbsp;Hg 
              decreased total mortality and fatal and non-fatal cardiovascular 
              events. Absolute benefits were greater in men than women, in people 
              aged over 70, and in those with prior cardiovascular events or wider 
              pulse pressure. The relative hazard rates associated with a 10&nbsp;mm&nbsp;Hg 
              higher initial systolic blood pressure were 1.26 (P&nbsp;=&nbsp;0.0001) 
              for total mortality, 1.22 (P&nbsp;=&nbsp;0.02) for stroke, but only 
              1.07 (P&nbsp;=&nbsp;0.37) for coronary events. Active treatment 
              reduced total mortality (RR 0.87, 95% CI 0.78 to 0.98, P&nbsp;=&nbsp;0.02). 
              <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i1?fn=document-frame.htm&amp;f=templates#REF123">[123]</A></font> 
              <B>Target diastolic blood pressure:</B> We found one RCT (18&nbsp;790 
              people, mean age 62 years, diastolic blood pressures between 100–115&nbsp;mm&nbsp;Hg), 
              which aimed to evaluate the effects on cardiovascular risk of target 
              diastolic blood pressures of 90, 85, and 80&nbsp;mm&nbsp;Hg. <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i1?fn=document-frame.htm&amp;f=templates#REF124">[124]</A> 
              However, mean achieved diastolic blood pressures were 85, 83, and 
              81&nbsp;mm&nbsp;Hg, which limited power to detect differences among 
              groups. There were no significant differences in major cardiovascular 
              events among the three groups.</P>
          </TD></TR></TBODY></TABLE>
      <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
        <TBODY>
        <TR>
          <TD>
            <P align=justify><FONT color=#0033cc><A name=I1-HARMS><B>Harms: 
            </B></A></FONT><B>Mortality and major morbidity:</B> One systematic 
            review of RCTs comparing diuretics and ß blockers versus placebo 
            found no increase in non-cardiovascular mortality in treated people. 
            <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i1?fn=document-frame.htm&amp;f=templates#REF122">[122]</A> 
            One systematic review (9 case control and 3 cohort studies) found 
            that long term diuretic use may be associated with an increased risk 
            of renal cell carcinoma (OR in case control studies 1.55, 95% CI 1.4 
            to 1.7). <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i1?fn=document-frame.htm&amp;f=templates#REF125">[125]</A> 
            Absolute risks cannot be calculated from these studies, but renal 
            cell carcinoma is rare, so the absolute risk increase of any real 
            effect would be correspondingly small. Renal cell carcinoma can 
            cause hypertension; this fact may have confounded the results of 
            these studies. <B>Quality of life and tolerability:</B> One 
            systematic review and several recent trials found that quality of 
            life was not adversely affected and may be improved in those who 
            remain on treatment. <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i1?fn=document-frame.htm&amp;f=templates#REF126">[126]</A> 
            <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i1?fn=document-frame.htm&amp;f=templates#REF127">[127]</A> 
            </P></TD></TR></TBODY></TABLE>
      <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
        <TBODY>
        <TR>
          <TD>
            <P align=justify><FONT color=#0033cc><A name=I1-COMMENT><B>Comment: 
            </B></A></FONT>Trials included people who were healthier than the 
            general population, with lower rates of cardiovascular risk factors, 
            cardiovascular disease, and comorbidity. People with higher 
            cardiovascular risk can expect greater short term absolute risk 
            reduction than seen in the trials, whereas people with major 
            competing risks such as terminal cancer or end stage Alzheimer's 
            disease can expect smaller risk reduction. In the systematic review, 
            <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i1?fn=document-frame.htm&amp;f=templates#REF122">[122]</A> 
            five of the trials were in middle aged adults with mild to moderate 
            hypertension. Seven of the trials were in people older than 60 
            years. On average, every 1000 person years of treatment in older 
            adults prevented five strokes (95% CI 2 to 8), three coronary events 
            (95% CI 1 to 4), and four cardiovascular deaths (95% CI 1 to 8). 
            Drug treatment in middle aged adults prevented one stroke (95% CI 0 
            to 2) for every 1000 person years of treatment and did not 
            significantly affect coronary events or 
      mortality.</P></TD></TR></TBODY></TABLE><BR><A name=references></A>
      <TABLE cellSpacing=0 cellPadding=0 border=0>
        <TBODY>
        <TR>
          <TD width=90 bgColor=#404040><IMG height=2 src="" width=1 
            align=absMiddle border=0></TD>
          <TD vAlign=bottom width="100%" bgColor=#404040><IMG height=2 src="" 
            width=1 align=absMiddle border=0></TD></TR>
        <TR>
          <TD class=key-message id=key-message width=90 
            bgColor=#404040><B>References</B></TD>
          <TD width="100%">&nbsp;</TD></TR></TBODY></TABLE><BR>
      <TABLE cellPadding=2 width="100%" align=center>
        <TBODY>
        <TR><A class=reference id=reference name=REF122></a>
          <TD class=reference id=reference vAlign=top width=15>122. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Gueyffier 
            F, Froment A, Gouton M. New meta-analysis of treatment trials of 
            hypertension: improving the estimate of therapeutic benefit. <EM>J 
            Hum Hypertens</EM> 1996;10:1–8. Search date 1997; primary source 
            Medline. <A style="FONT-SIZE: 8pt" 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=96219361");'>[PubMed]</A></TD></TR>
        <TR><A class=reference id=reference name=REF123></a>
          <TD class=reference id=reference vAlign=top width=15>123. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Staessen 
            JA, Gasowski J, Wang JG, et al. Risks of untreated and treated 
            isolated systolic hypertension in the elderly: meta-analysis of 
            outcome trials. <EM>Lancet</EM> 2000;355:865–872. Search date 1999; 
            primary sources other systematic reviews and reports from 
            collaborative trialists. <A style="FONT-SIZE: 8pt" 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20214375");'>[PubMed]</A></TD></TR>
        <TR><A class=reference id=reference name=REF124></a>
          <TD class=reference id=reference vAlign=top width=15>124. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Hansson L, 
            Zanchetti AZ, Carruthers SG, et al. Effects of intensive blood 
            pressure lowering and low-dose aspirin in patients with 
            hypertension: principal results of the hypertension optimal 
            treatment (HOT) trial. <EM>Lancet</EM> 1998;351:1755–1762. <A 
            style="FONT-SIZE: 8pt" 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=98297870");'>[PubMed]</A></TD></TR>
        <TR><A class=reference id=reference name=REF125></a>
          <TD class=reference id=reference vAlign=top width=15>125. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Grossman E, 
            Messerli FH, Goldbourt U. Does diuretic therapy increase the risk of 
            renal cell carcinoma? <EM>Am J Cardiol</EM> 1999;83:1090–1093. 
            Search dates 1966 to 1998; primary sources Medline. <A 
            style="FONT-SIZE: 8pt" 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=99204801");'>[PubMed]</A></TD></TR>
        <TR><A class=reference id=reference name=REF126></a>
          <TD class=reference id=reference vAlign=top width=15>126. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Beto JA, 
            Bansal VK. Quality of life in treatment of hypertension: a 
            meta-analysis of clinical trials. <EM>Am J Hypertens</EM> 
            1992;5:125–133. Search date 1990; primary sources Medline, ERIC. <A 
            style="FONT-SIZE: 8pt" 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=92247409");'>[PubMed]</A></TD></TR>
        <TR><A class=reference id=reference name=REF127></a>
          <TD class=reference id=reference vAlign=top width=15>127. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Croog SH, 
            Levine S, Testa MA. The effects of antihypertensive therapy on 
            quality of life. <EM>N Engl J Med</EM> 1986;314:1657–1664. <A 
            style="FONT-SIZE: 8pt" 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=86230742");'>[PubMed]</A></TD></TR></TBODY></TABLE>
      <TABLE width="100%" border=0>
        <TBODY>
        <TR>
          <TD vAlign=bottom width="50%">
          <TD align=right width="50%"><A 
            href="http://www.evidence.org/lpBinCE/lpext.dll?f=id&amp;id=201106&amp;t=document-frame.htm&amp;p=copyright.html&amp;2.0"><IMG 
            alt="BMJ - Clinical Evidence" src="0205_i1_files/ce-pagebrand.jpg" 
            border=0></A></TD></TR>
        <TR>
          <TD align=left width="50%">
          <TD align=right width="50%"><A 
            href="http://www.evidence.org/lpBinCE/lpext.dll?f=id&amp;id=201106&amp;t=document-frame.htm&amp;p=copyright.html&amp;2.0"><SPAN 
            style="FONT-SIZE: 8pt; font-face: arial">© 2001 BMJ Publishing 
            Group</SPAN></A></TD></TR></TBODY></TABLE>
      <SCRIPT language=JavaScript>
			var purl = "0205.PDF"; 
</SCRIPT>

      <SCRIPT language=JavaScript src="0205_i1_files/stats.js" 
      type=text/javascript></SCRIPT>

      <SCRIPT language=JavaScript type=text/javascript><!--
  stats("MC-MTg0OQ==-45MT-Y2Nz","","","");
//--></SCRIPT>
      <NOSCRIPT><IMG height=1 src="" width=1 
  border=0></NOSCRIPT></TD></TR></TBODY></TABLE>
<FORM name=LPHitCountForm><INPUT type=hidden value=0 name=LPHitCount> 
</FORM></BODY></HTML>
